15315 Patient-reported outcomes with abrocitinib treatment in patients with moderate to severe atopic dermatitis: Results from a randomized, phase 3 clinical trial

Jonathan I. Silverberg; Arnon D. Cohen; Sonja Stander; Claire Feeney; Hernan Valdez; Pinaki Biswas; Michael C. Cameron; Robert A. Gerber

doi:10.1016/j.jaad.2020.06.228

15315 Patient-reported outcomes with abrocitinib treatment in patients with moderate to severe atopic dermatitis: Results from a randomized, phase 3 clinical trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.228 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB35

Author(s):

Jonathan I. Silverberg ◽

Arnon D. Cohen ◽

Sonja Stander ◽

Claire Feeney ◽

Hernan Valdez ◽

...

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Patient Reported Outcomes ◽

Severe Atopic Dermatitis ◽

Phase 3 ◽

Patient Reported

Download Full-text

Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.04.054 ◽

2016 ◽

Vol 75 (3) ◽

pp. 506-515 ◽

Cited By ~ 84

Author(s):

Eric L. Simpson ◽

Abhijit Gadkari ◽

Margitta Worm ◽

Weily Soong ◽

Andrew Blauvelt ◽

...

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Patient Reported Outcomes ◽

Adult Patients ◽

Controlled Clinical Trial ◽

Severe Atopic Dermatitis ◽

Meaningful Improvement ◽

Patient Reported

Download Full-text

JAAD Game Changers: Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.10.051 ◽

2019 ◽

Vol 80 (4) ◽

pp. 882 ◽

Cited By ~ 1

Author(s):

Eden Lake

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Patient Reported Outcomes ◽

Adult Patients ◽

Controlled Clinical Trial ◽

Severe Atopic Dermatitis ◽

Meaningful Improvement ◽

Patient Reported

Download Full-text

Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2020.12.560 ◽

2021 ◽

Vol 147 (2) ◽

pp. AB156

Author(s):

Amy McMichael ◽

Michael Cork ◽

Joyce Teng ◽

Ricardo Rojo ◽

Hernan Valdez ◽

...

Keyword(s):

Atopic Dermatitis ◽

Patient Reported Outcomes ◽

Severe Atopic Dermatitis ◽

Phase 3 ◽

Patient Reported ◽

Adolescent Patients

Download Full-text

Patient‐reported outcomes from the JADE COMPARE randomised phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17813 ◽

2021 ◽

Author(s):

J. P. Thyssen ◽

G. Yosipovitch ◽

C. Paul ◽

S.G. Kwatra ◽

C.‐Y. Chu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Patient Reported Outcomes ◽

Severe Atopic Dermatitis ◽

Phase 3 ◽

Patient Reported

Download Full-text

Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17109 ◽

2021 ◽

Author(s):

D Thaçi ◽

AM Soliman ◽

K Eyerich ◽

A Pinter ◽

M Sebastian ◽

...

Keyword(s):

Clinical Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Therapy ◽

Patient Reported Outcomes ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Patient Reported ◽

Acid Esters

Download Full-text

28194 Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: Pooled results from two phase 3 studies

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.727 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB178

Author(s):

Eric L. Simpson ◽

Matthias Augustin ◽

Diamant Thaçi ◽

Laurent Misery ◽

Jonathan I. Silverberg ◽

...

Keyword(s):

Atopic Dermatitis ◽

Patient Reported Outcomes ◽

Phase 3 ◽

Two Phase ◽

Patient Reported

Download Full-text

27237 Effect of abrocitinib vs dupilumab and placebo on patient-reported outcomes (PROs) in moderate-to-severe atopic dermatitis (AD) in JADE COMPARE

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.551 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB133

Author(s):

Gil Yosipovitch ◽

Jacob P. Thyssen ◽

Carle Paul ◽

Shawn G. Kwatra ◽

Chia-Yu Chu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Patient Reported Outcomes ◽

Severe Atopic Dermatitis ◽

Patient Reported

Download Full-text

Short Course Of Oral Prednisolone Improves Physician Reported Clinical Scores and Patient Reported Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2018.12.406 ◽

2019 ◽

Vol 143 (2) ◽

pp. AB134 ◽

Cited By ~ 1

Author(s):

Emma Price ◽

Sai Sakktee Krisna ◽

Karen J. Howie ◽

Rashie Brar ◽

Eman Alasgah ◽

...

Keyword(s):

Atopic Dermatitis ◽

Patient Reported Outcomes ◽

Oral Prednisolone ◽

Severe Atopic Dermatitis ◽

Clinical Scores ◽

Short Course ◽

Patient Reported

Download Full-text

15054 Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.198 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB28

Author(s):

Peter Lio ◽

Audrey Nosbaum ◽

Tracy Cardillo ◽

Amy DeLozier ◽

Margaret Gamalo ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Severe Atopic Dermatitis ◽

Inadequate Response ◽

Phase 3 ◽

Skin Symptoms ◽

Patient Reported

Download Full-text

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

Breast Diseases A Year Book Quarterly ◽

10.1016/j.breastdis.2016.10.015 ◽

2016 ◽

Vol 27 (4) ◽

pp. 281-282

Author(s):

M.C. Stauder

Keyword(s):

Clinical Trial ◽

Ductal Carcinoma In Situ ◽

Carcinoma In Situ ◽

Patient Reported Outcomes ◽

Ductal Carcinoma ◽

Phase 3 ◽

Double Blind ◽

Patient Reported

Download Full-text